Mechanism of action
Morphine is a potent agonist at μ-opioid receptors (MOR), with weaker activity at κ and δ receptors. It binds to G-protein coupled receptors in the central nervous system (brain and spinal cord) and peripheral tissues.
Receptor-level effects
Activation of μ-opioid receptors produces several effects:
- Inhibition of adenylyl cyclase reduces cAMP formation
- Opening of potassium channels causes hyperpolarization of neurons
- Closing of voltage-gated calcium channels reduces neurotransmitter release
- Inhibition of ascending pain pathways in the dorsal horn of the spinal cord
- Activation of descending inhibitory pathways from periaqueductal gray and rostral ventromedial medulla
Supraspinal and spinal analgesia
Morphine modulates pain perception at multiple levels. In the brain, it acts on limbic system structures to alter the emotional response to pain. At the spinal cord level, it inhibits release of substance P and other nociceptive neurotransmitters from primary afferent neurons. The net result is reduced transmission of pain signals and decreased perception of pain intensity.
Receptor subtypes and clinical effects
μ-Opioid receptor activation in the medullary respiratory center causes respiratory depression by decreasing the sensitivity of chemoreceptors to carbon dioxide. This effect is dose-dependent and represents the primary danger in morphine overdose. Analgesia and euphoria are mediated through μ-receptor activation in multiple CNS sites including the periaqueductal gray, thalamus, and limbic system. Physical dependence and decreased gastrointestinal motility also result from μ-receptor activation.
- Morphine activates μ-opioid receptors, causing analgesia and respiratory depression via medullary chemoreceptor suppression
- Morphine-6-glucuronide (M6G) is an active metabolite that accumulates in renal failure, causing prolonged effects
- Constipation occurs in nearly all patients and does not develop tolerance; requires prophylactic laxatives
- Naloxone reverses morphine toxicity but has shorter duration than morphine, risking re-sedation
- Morphine undergoes significant first-pass metabolism; oral bioavailability is only 20-40%
- Classic triad of opioid toxicity: respiratory depression, miosis (pinpoint pupils), and CNS depression
- Morphine causes histamine release leading to hypotension, pruritus, and flushing, especially with rapid IV push
- Concurrent benzodiazepines and morphine dramatically increase respiratory depression and overdose risk
Indications
Morphine is indicated for management of pain severe enough to require opioid analgesia and for which alternative treatments are inadequate.
Acute pain
- Myocardial infarction: reduces pain, anxiety, and preload
- Trauma and burns: severe acute pain management
- Postoperative pain: patient-controlled analgesia (PCA) or scheduled dosing
- Acute pancreatitis: historically avoided due to sphincter of Oddi spasm concerns, but now considered acceptable
- Renal colic: effective but NSAIDs often preferred as first-line
Chronic pain
- Cancer pain: cornerstone of WHO analgesic ladder Step 3
- Palliative care: end-of-life pain and dyspnea management
- Chronic non-cancer pain: reserved for cases where benefits outweigh risks after other therapies have failed
Other indications
- Acute pulmonary edema: reduces preload and anxiety (historical use, less common now)
- Dyspnea in terminal illness: palliative symptom management
- Premedication for anesthesia: anxiolysis and analgesia
Morphine is available in immediate-release and extended-release formulations. Extended-release products are used for chronic pain requiring around-the-clock opioid therapy.
Pharmacokinetics
Understanding morphine's pharmacokinetics is essential for predicting clinical effects and managing adverse reactions.
Absorption and bioavailability
Oral morphine undergoes significant first-pass metabolism in the liver, resulting in bioavailability of only 20-40%. This is why oral doses are substantially higher than parenteral doses for equivalent analgesia. Peak plasma concentrations occur 30-60 minutes after oral immediate-release administration and 1-2 hours after intramuscular injection.
Distribution
Morphine has a volume of distribution of approximately 3-4 L/kg. It crosses the blood-brain barrier less readily than more lipophilic opioids like fentanyl, resulting in slower onset of CNS effects. Morphine crosses the placenta and is distributed into breast milk.
Metabolism
Morphine is primarily metabolized in the liver via glucuronidation (Phase II metabolism). The two major metabolites are:
- Morphine-3-glucuronide (M3G): inactive or possibly antagonistic, may contribute to neurotoxicity
- Morphine-6-glucuronide (M6G): active metabolite with analgesic potency equal to or greater than morphine, longer half-life
M6G accumulation in renal failure can cause prolonged respiratory depression and CNS toxicity, requiring dose adjustment or alternative opioid selection.
Elimination
Metabolites are excreted primarily in urine (90%). The elimination half-life of morphine is 2-4 hours, but M6G has a longer half-life of 6-8 hours. In patients with renal impairment, M6G accumulates significantly, necessitating dose reduction or avoidance.
Adverse effects
Morphine's adverse effects result from μ-opioid receptor activation throughout the body.
Central nervous system
- Respiratory depression: most dangerous effect, results from decreased sensitivity of medullary chemoreceptors to CO₂
- Sedation and drowsiness: common, dose-dependent
- Euphoria or dysphoria: variable patient response
- Miosis: pinpoint pupils are a classic sign of opioid toxicity
- Seizures: rare, may occur with very high doses or in renal failure (M3G accumulation)
- Increased intracranial pressure: due to vasodilation from hypercapnia secondary to respiratory depression
Gastrointestinal
- Constipation: occurs in nearly all patients, does not develop tolerance, requires prophylactic laxatives
- Nausea and vomiting: stimulation of chemoreceptor trigger zone, affects 25-30% of patients
- Delayed gastric emptying: slowed GI motility
- Biliary colic: sphincter of Oddi spasm increases biliary pressure
Cardiovascular
- Histamine release: can cause hypotension, pruritus, flushing; more common with rapid IV administration
- Bradycardia: vagal stimulation
- Orthostatic hypotension: peripheral vasodilation
Other effects
- Pruritus: histamine-mediated or central mechanism, common side effect
- Urinary retention: increased urethral and bladder sphincter tone
- Bronchospasm: histamine release, particularly in asthmatic patients
Tolerance and dependence
Physical dependence develops with regular use. Tolerance develops to analgesia, euphoria, and respiratory depression, but not to constipation or miosis. Abrupt discontinuation causes withdrawal syndrome with lacrimation, rhinorrhea, yawning, sweating, piloerection, mydriasis, tremor, tachycardia, hypertension, and gastrointestinal distress.
Contraindications and warnings
Absolute contraindications
- Significant respiratory depression or acute/severe bronchial asthma in unmonitored settings
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to morphine or any formulation component
- Concurrent or recent (within 14 days) MAO inhibitor use: risk of serotonin syndrome and potentiated opioid effects
Black box warnings
Morphine carries multiple FDA black box warnings:
- Addiction, abuse, and misuse: even at therapeutic doses
- Life-threatening respiratory depression: especially during initiation and dose increases
- Accidental ingestion: especially in children, can be fatal
- Neonatal opioid withdrawal syndrome: with prolonged maternal use during pregnancy
- Cytochrome P450 3A4 interaction: with extended-release formulations
- Concomitant use with benzodiazepines or other CNS depressants: profound sedation, respiratory depression, coma, death
Special populations
Pregnancy (Category C): crosses placenta; chronic use can cause neonatal opioid withdrawal syndrome. Use in labor can cause neonatal respiratory depression.
Renal impairment: M6G accumulation requires dose reduction; consider alternative opioids like fentanyl or hydromorphone.
Hepatic impairment: reduced clearance, increased bioavailability; initiate at lower doses.
Elderly patients: increased sensitivity, higher risk of respiratory depression and confusion.
Head injury or increased intracranial pressure: can obscure neurological assessment and worsen ICP through hypercapnia.
Acute pancreatitis: historically controversial due to sphincter of Oddi spasm, but evidence suggests morphine is safe and effective.
Drug interactions
Morphine has numerous clinically significant drug interactions.
CNS depressants
Benzodiazepines, alcohol, barbiturates, other opioids, sedative-hypnotics, general anesthetics, phenothiazines, tranquilizers, skeletal muscle relaxants: additive CNS and respiratory depression. This combination has been implicated in numerous overdose deaths. If co-administration is necessary, use lowest effective doses and monitor closely.
Serotonergic drugs
SSRIs, SNRIs, TCAs, triptans, MAO inhibitors, linezolid: increased risk of serotonin syndrome with symptoms including agitation, hyperthermia, hyperreflexia, clonus, tremor, diaphoresis, and altered mental status. MAO inhibitors are contraindicated within 14 days of morphine use.
Anticholinergic drugs
Antihistamines, antiparkinson drugs, TCAs: increased risk of urinary retention, severe constipation, paralytic ileus.
Mixed agonist-antagonist opioids
Pentazocine, nalbuphine, butorphanol, buprenorphine: may reduce morphine's analgesic effect and precipitate withdrawal in opioid-dependent patients. Avoid concurrent use.
CYP interactions
While morphine is primarily metabolized by glucuronidation, not CYP450 enzymes, CYP3A4 inhibitors (azole antifungals, macrolides, protease inhibitors) and inducers (rifampin, carbamazepine, phenytoin) may affect morphine levels to a lesser degree than other opioids.
Diuretics
Morphine may reduce the efficacy of diuretics in patients with heart failure.
Muscle relaxants
Enhanced neuromuscular blockade and respiratory depression with neuromuscular blocking agents.
Clinical pearls
Exam-relevant concepts
Morphine vs. fentanyl: Morphine is less lipophilic, slower onset, longer duration, causes more histamine release. Fentanyl is highly lipophilic, rapid onset, shorter duration, minimal histamine release, and preferred in hemodynamically unstable patients.
Morphine vs. meperidine: Meperidine is generally avoided due to toxic metabolite normeperidine, which accumulates in renal failure and causes seizures. Morphine is preferred for most indications, though meperidine has some use for rigors and postoperative shivering.
Equianalgesic dosing: 10 mg IV morphine ≈ 30 mg oral morphine (due to first-pass metabolism) ≈ 100 μg IV fentanyl ≈ 1.5 mg IV hydromorphone. These conversions are essential for rotating opioids or switching routes.
Reversal of morphine toxicity
Naloxone is a pure μ-opioid receptor antagonist used to reverse morphine-induced respiratory depression. Initial dose is 0.4-2 mg IV, which can be repeated. Be aware that naloxone's duration of action (30-90 minutes) is shorter than morphine's, so re-sedation and respiratory depression can occur, requiring repeated dosing or continuous infusion. In opioid-dependent patients, naloxone precipitates acute withdrawal.
Patient-controlled analgesia (PCA)
Morphine PCA allows patients to self-administer predetermined doses within safety limits. Typical settings include a bolus dose, lockout interval (usually 6-10 minutes), and maximum hourly limit. This approach improves patient satisfaction and pain control while reducing total opioid consumption compared to scheduled dosing.
Morphine in myocardial infarction
Historically a cornerstone of MI management, morphine reduces pain, anxiety, sympathetic outflow, and venous return (preload reduction). Recent data suggest possible delayed absorption of oral antiplatelet agents and worse outcomes, leading to more cautious use and preference for analgesics like fentanyl in some protocols.
Misconceptions about addiction
True addiction (psychological dependence with compulsive drug-seeking behavior) is uncommon when morphine is used appropriately for severe pain under medical supervision. Physical dependence and tolerance are expected physiologic responses, distinct from addiction. Pain should not be undertreated due to unfounded addiction fears in acute or cancer pain settings.
Morphine's M-effects: Miosis, Mental clouding, Myoclonus (high doses), Medullary depression (respiratory), Motility decreased (GI), M3G and M6G metabolites
Practice questions
1. A 68-year-old man with end-stage renal disease on hemodialysis is admitted for severe pain from metastatic bone cancer. He receives morphine 10 mg IV every 4 hours. On hospital day 3, he becomes increasingly somnolent with respiratory rate of 8 breaths/minute and pinpoint pupils. Naloxone partially reverses his symptoms, but he becomes sedated again 90 minutes later. Which of the following best explains this clinical course?
2. A 45-year-old woman is prescribed extended-release morphine for chronic back pain. She develops severe constipation despite adequate fluid and fiber intake. Which of the following best explains why constipation persists despite continued morphine therapy?
3. A 32-year-old man who uses intravenous heroin daily presents to the emergency department with altered mental status. He is found unresponsive with respiratory rate of 4 breaths/minute, oxygen saturation 82%, and pinpoint pupils. After initial stabilization with naloxone 2 mg IV, he awakens and becomes agitated, diaphoretic, and tachycardic. He demands to leave against medical advice. What is the most appropriate next step in management?
Frequently asked questions
How does morphine work?
Morphine works by binding to and activating μ-opioid receptors in the brain and spinal cord, which inhibits pain signal transmission. It acts through multiple mechanisms including inhibition of adenylyl cyclase, opening of potassium channels causing neuronal hyperpolarization, and closure of voltage-gated calcium channels reducing neurotransmitter release. This results in decreased perception of pain at both spinal and supraspinal levels. μ-Opioid receptor activation mediates both analgesia and respiratory depression through effects on different CNS regions.
What are the side effects of morphine?
The most serious side effect is respiratory depression, which is dose-dependent and the primary cause of opioid overdose deaths. Common side effects include constipation (occurs in nearly all patients), nausea and vomiting, sedation, dizziness, and pruritus. Morphine causes histamine release leading to flushing, hypotension, and itching, especially with rapid intravenous administration. Other effects include miosis (pinpoint pupils), urinary retention, and euphoria or dysphoria. With chronic use, physical dependence and tolerance develop.
Is morphine a controlled substance?
Yes, morphine is a Schedule II controlled substance in the United States under the Controlled Substances Act. This classification reflects its accepted medical use but high potential for abuse and severe psychological or physical dependence. Schedule II drugs require a written prescription from a licensed practitioner (electronic prescribing is now permitted in most jurisdictions), and the prescription cannot be refilled—a new prescription is required for each dispensing. Strict record-keeping and storage requirements apply to healthcare facilities and pharmacies.
Morphine vs fentanyl: what is the difference?
Morphine and fentanyl differ significantly in potency, pharmacokinetics, and side effect profiles. Fentanyl is approximately 100 times more potent than morphine and highly lipophilic, resulting in rapid onset (1-2 minutes IV) and shorter duration of action. Morphine is less lipophilic with slower onset (5-10 minutes IV) but longer duration. Morphine causes significant histamine release leading to hypotension and pruritus, while fentanyl causes minimal histamine release, making it preferred in hemodynamically unstable patients. Fentanyl is also preferred in renal failure because it lacks active metabolites, unlike morphine's M6G.
Can morphine be used in renal failure?
Morphine should be used with extreme caution in renal failure and is generally not the preferred opioid in this population. The active metabolite morphine-6-glucuronide (M6G) is renally eliminated and accumulates significantly in renal impairment, leading to prolonged analgesia, excessive sedation, and potentially life-threatening respiratory depression. If morphine must be used in renal failure, doses should be substantially reduced and dosing intervals prolonged. Alternative opioids like fentanyl (no active metabolites) or hydromorphone (less problematic metabolites) are generally preferred in patients with significant renal dysfunction.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N02AA01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.